Artiva Biotherapeutics (ARTV) Stock Overview
A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ARTV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Artiva Biotherapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.48 |
| 52 Week High | US$15.49 |
| 52 Week Low | US$1.47 |
| Beta | 0 |
| 1 Month Change | 65.93% |
| 3 Month Change | 30.23% |
| 1 Year Change | -59.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.67% |
Recent News & Updates
Shareholder Returns
| ARTV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 48.8% | 3.0% | 1.1% |
| 1Y | -59.1% | 2.7% | 16.7% |
Return vs Industry: ARTV underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: ARTV underperformed the US Market which returned 16.7% over the past year.
Price Volatility
| ARTV volatility | |
|---|---|
| ARTV Average Weekly Movement | 36.8% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARTV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ARTV's weekly volatility has increased from 24% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 105 | Fred Aslan | www.artivabio.com |
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Artiva Biotherapeutics, Inc. Fundamentals Summary
| ARTV fundamental statistics | |
|---|---|
| Market cap | US$106.50m |
| Earnings (TTM) | -US$75.13m |
| Revenue (TTM) | n/a |
Is ARTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARTV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$75.13m |
| Earnings | -US$75.13m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ARTV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/22 23:49 |
| End of Day Share Price | 2025/10/22 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Artiva Biotherapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Edward White | H.C. Wainwright & Co. |
| Emily Bodnar | H.C. Wainwright & Co. |